Rhizen Pharma Starts Dosing in Phase I/Ib Study of Novel PARP Inhibitor for Advanced Solid Tumors
Rhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read moreRhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read moreAgilent’s PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying Triple-Negative Breast Cancer (TNBC) patients for
Read moreThe first two projects funded within the translational BRIDGE beLAB1407 collaboration will focus on new mechanisms to treat cancer, Evotec
Read moreKEYTRUDA® has been granted approval as a first-choice treatment in combination with chemotherapy for patients with locally recurrent unresectable or
Read moreA pan-tumor IHC screen identified high fibroblast activating protein (FAP) expression in multiple tumor types that correlated with in vitro
Read moreKite Pharma, a Gilead Company, announced on Friday that the U.S. FDA has granted approval for CAR T-cell therapy Tecartus®
Read moreGenmab A/S and Seagen Inc. revealed that the first and only approved antibody-drug conjugate (ADC) known as TIVDAK™ (tisotumab vedotin-tftv),
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreThe NHS-Galleri Trial is being launched to evaluate whether a blood test may help identify cancer earlier when combined with
Read moreAmgen’s first-in-class KRAS G12C inhibitor LumykrasTM (sotorasib) has been granted Conditional Marketing Authorisation by the Medicines and Healthcare products Regulatory
Read more